Kelch repeat and BTB domain-containing protein 11 (KBTBD11) is a member of the KBTBD subfamily of proteins that possess a BTB domain and Kelch repeats. Despite the presence of the Kbtbd11 gene in mammalian genomes, there are few reports about KBTBD11 at present. In this study, we identified the novel protein KBTBD11 as a negative regulator of osteoclast differentiation. We found that expression of KBTBD11 increased during osteoclastogenesis. Small-interfering-RNA-mediated knockdown of KBTBD11 enhanced osteoclast formation, and markedly increased the expression of several osteoclast marker genes compared with control cells. Conversely, KBTBD11 overexpression impaired osteoclast differentiation, and decreased the expression of osteoclast marker genes. Among six major signaling pathways regulating osteoclast differentiation, KBTBD11 predominantly influenced the nuclear factor of activated T cell cytoplasmic-1 (NFATc1) pathway. Mechanistically, KBTBD11 was found to interact with an E3 ubiquitin ligase, Cullin3. Further experiments involving immunoprecipitation and treatment with MG132, a proteasome inhibitor, showed that the KBTBD11-Cullin3 promotes ubiquitination and degradation of NFATc1 by the proteasome. Considering that NFATc1 is an essential factor for osteoclast differentiation, the KBTBD11 and Cullin3 probably regulate the levels of NFATc1 through the ubiquitin-proteasome degradation system. Thus, KBTBD11 negatively modulates osteoclast differentiation by controlling Cullin3-mediated ubiquitination of NFATc1.
Results
KBTBD11 is upregulated during osteoclast differentiation. Recently, by DNA microarray analysis, our group demonstrated that 1,363 genes are upregulated and 881 genes are downregulated during osteoclastogenesis of bone-marrow macrophages 17 . Among the upregulated genes, we found an uncharacterized gene, Kbtbd11, as well as other osteoclast marker genes, such as calcitonin receptor (Calcr), cathepsin K (Ctsk), transmembrane 7 superfamily member 4 (Dcstamp), and tartrate-resistant acid phosphatase (Acp5; Fig. 1a ).
To explore whether the expression level of KBTBD11 increases during osteoclast differentiation, we determined the mRNA level of Kbtbd11 in mouse macrophage-like RAW-D cells. Determination by real-time polymerase chain reaction (RT-PCR) showed that Kbtbd11 level gradually increased after RANKL stimulation (Fig. 1b) . The mRNA level of Kbtbd11 at 72 h after stimulation reached a ~70-fold higher level than that in unstimulated cells (Fig. 1b) . We also examined the protein levels of KBTBD11 in RAW-D cells during RANKL-induced osteoclastogenesis (Fig. 1c ). Western blot analysis revealed that the endogenous KBTBD11 in RAW-D cells was detected as a protein with a molecular mass of ~67 kDa. The KBTBD11 levels in RANKL-stimulated cells gradually increased as compared with unstimulated cells, although this level transiently decreased after 1 day of stimulation ( Fig. 1c ). Thus, KBTBD11 was upregulated during osteoclast differentiation.
Knockdown of KBTBD11 enhances osteoclast differentiation.
To study the role of KBTBD11 during osteoclast differentiation, we performed siRNA-mediated knockdown experiments. The efficacy of the KBTBD11 knockdown in RANKL-stimulated RAW-D cells was determined ( Fig. 2a ). Depletion of KBTBD11 by siRNA #1 in the cells yielded an approximately 60% reduction, whereas siRNA #2, and #3 caused an approximately 50% and 30% reduction, respectively, as compared to the control siRNA ( Fig. 2a ). Therefore, we selected siRNA #1 for following knockdown experiments, because the knockdown efficacy was the highest. Upon stimulation with RANKL for 3-5 days, KBTBD11-depleted cells displayed larger formation in osteoclasts compared with the control (Fig. 2b ). The number of TRAP-positive multinucleated cells (MNCs) was significantly higher in KBTBD 11 knockdown cells than that in control cells at 3 and 5 days (Fig. 2c ). The number of control cells peaked on the 4th day after stimulation and fell immediately on the 5th days ( Fig. 2c ). In KBTBD11 knockdown cells, however, the peaks of number persisted for 3 to 4 days, and this number was declined on the 5th day of stimulation ( Fig. 2c ). Moreover, the nuclear number of KBTBD11-knockdown osteoclasts was greater than that of control osteoclasts ( Fig. 2d ).
To determine whether KBTBD11 knockdown enhances osteoclast maturation, we measured the mRNA expression of some osteoclast marker genes. RT-PCR analysis showed that the expression of Nfatc1, Src, Ctsk, osteoclast stimulatory transmembrane protein (Ocstamp), Dcstamp, and matrix metalloprotease 9 (Mmp9) was significantly higher in KBTBD11-knockdown osteoclasts than in control cells ( Supplementary Fig. S1A ). These results imply that KBTBD11-depleted osteoclasts display enhanced maturation compared with control cells.
Next, to investigate bone resorption activity, we performed a pit formation assay on control and KBTBD11-depleted osteoclasts. As expected, KBTBD11-knockdown osteoclasts showed a marked increase in resorption activity compared with control osteoclasts (Fig. 3a ). When we calculated the resorption area, this area generated by KBTBD11-knockdown osteoclasts was significantly larger than that generated by the control osteoclasts ( Fig. 3b) .
To explore the molecular mechanisms underlying the enhanced maturation of KBTBD11-knockdown osteoclasts, we investigated the expression of signaling molecules in control and KBTBD11-knockdown RAW-D macrophages after RANKL stimulation. Western blot analysis revealed that the protein level of NFATc1 and CTSK in KBTBD11-knockdown RAW-D cells was markedly higher than that in control cells ( Fig. 4a,b) . Moreover, the protein levels of Src were slightly higher in KBTBD11-knockdown RAW-D cells than in control cells, although there was no statistically significant difference ( Fig. 4a,b ). Upon stimulation with RANKL, the phosphorylation levels www.nature.com/scientificreports www.nature.com/scientificreports/ of p-38 and Akt increased in KBTBD11-knockdown RAW-D cells compared to control cells ( Fig. 4c,d ). However, the phosphorylation levels of IκB were comparable between control and KBTBD11-knockdown RAW-D cells ( Fig. 4c,d) . Conversely, the phosphorylation levels of JNK and ERK were lower in KBTBD11-knockdown RAW-D cells than in control cells ( Fig. 4c,d ).
Overexpression of KBTBD11 impairs osteoclast differentiation. To confirm that KBTBD11 overexpression prevents osteoclast differentiation, we performed overexpression experiments on RAW-D cells with a www.nature.com/scientificreports www.nature.com/scientificreports/ vector encoding KBTBD11-green fluorescent protein (GFP) fusion or GFP alone (control). The mRNA expression level of KBTBD11-GFP increased by ~70-fold compared with that of control cells (Fig. 5a ). Western blot analysis with anti-GFP antibody revealed that the KBTBD11-GFP fusion protein was detected as a band with a molecular mass of approximately 95 kDa ( Fig. 5b ). Upon RANKL stimulation for 3-5 days, TRAP staining analysis indicated that KBTBD11-overexpressing osteoclasts were apparently smaller in size compared to control osteoclasts ( Fig. 5c ). After the number of TRAP-positive MNCs was determined, the number of KBTBD11-overexpressing osteoclasts was significantly lower than that of control osteoclasts (Fig. 5d ). www.nature.com/scientificreports www.nature.com/scientificreports/ To determine investigate whether KBTBD11-overexpressing osteoclasts undergo delayed maturation, we measured the mRNA levels of some osteoclast marker genes in control and KBTBD11-overexpressing osteoclasts ( Supplementary Fig. S2 ). Control and KBTBD11-overexpressing RAW-D cells were cultured with RANKL (100 ng/mL) for 3 days. RT-PCR analysis of cells in both groups showed that mRNA levels of Nfatc1, Src, Ctsk, Ocstamp, and Mmp9 were significantly lower in KBTBD11-overexpressing osteoclasts compared with control cells, although the mRNA levels of Dcstamp were comparable between control and KBTBD11-overexpressing osteoclasts ( Supplementary Fig. S2 ).
We further compared bone resorption activities between control and KBTBD11-overexpressing osteoclasts. The pit formation assay showed that KBTBD11-overexpressing osteoclasts exhibited a markedly lower resorption activity compared with control osteoclasts ( Supplementary Fig. S3A ). The respective calculated resorption area of KBTBD11-overexpressing osteoclasts was significantly lower than that of control osteoclasts ( Supplementary  Fig. S3B ). These results indicate that KBTBD11 overexpression impairs almost marker gene expression and bone resorption activity in such osteoclasts compared with control osteoclasts.
Next, to examine signaling pathways affected in KBTBD11-overexpressing osteoclasts, we analyzed the signaling molecules in control and KBTBD11-overexpressing RAW-D cells upon stimulation with RANKL ( Fig. 6 ). Western blot analysis showed that expression levels of NFATc1 and CTSK were markedly decreased in KBTBD11-overexpressing RAW-D cells compared with control cells (Fig. 6a ). In addition, the protein levels of Src were also lower in KBTBD11-overexpressing RAW-D cells than in control cells ( Fig. 6a ). We also examined nuclear translocation of NFATc1 in control and KBTBD11-overexpressing osteoclasts. As expected, the levels of nuclear-translocated NFATc1 in KBTBD11-overexpressing cells were significantly lower than those in control cells ( Supplementary Fig. S4 ). Upon stimulation with RANKL, the phosphorylation levels of some relevant molecules, such as IκB and p-38 were almost indistinguishable between control and KBTBD11-overexpressing RAW-D cells, although there are some differences in each time ( Fig. 6c,d) . The phosphorylation levels of JNK and ERK were slightly higher in KBTBD11-overexpressing RAW-D cells than in control cells ( Fig. 6c,d ). However, the phosphorylation levels of Akt decreased in KBTBD11-overexpressing RAW-D cells compared to control cells ( Fig. 6c,d ). www.nature.com/scientificreports www.nature.com/scientificreports/ KBTBD11 interacts with the E3 ubiquitin ligase Cullin3. Generally, Kelch-BTB proteins function as adaptor proteins of the E3 ubiquitin ligase Cullin3 20 . Therefore, we examined whether KBTBD11 interacts with Cullin3. The cell lysates from control and KBTBD11-overexpressing RAW-D cells were immunoprecipitated with an anti-Cullin3 antibody, and the immune-complex was subjected to western blot analysis with an anti-GFP antibody. The coimmunoprecipitated protein band corresponding to KBTBD11-GFP was detected at a molecular mass of approximately 95 kDa ( Fig. 7) . These results suggest that KBTBD11 interacts with Cullin3.
NFATc1 is a ubiquitinated substrate for KBTBD11 and Cullin3. When we analyzed some candidate proteins as substrates, we found NFATc1 to be a ubiquitinated substrate ( Fig. 8 ). As shown in Fig. 8a , the NFATc1 expression was markedly induced on day 2 after RANKL stimulation, but it decreased on day 4. Treatment with MG132, an inhibitor of the proteasome, induced accumulation of NFATc1 on day 0 and day 4 after RANKL stimulation, although it slightly increased the levels of NFATc1 on day 2 (Fig. 8a ). However, accumulation of NFATc1 on day 2 after RANKL stimulation was found as poly-ubiqutinated proteins (Fig. 8b ). To analyze ubiquitinated NFATc1, we performed immunoprecipitation with anti-NFATc1 antibody followed by western blot analysis with anti-ubiquitin antibody ( Fig. 8b and c) . After RANKL stimulation for 2 days, the levels of ubiquitinated NFATc1 markedly increased in KBTBD11-overexpressing cells treated with MG132 for 5 h compared with untreated cells (Fig. 8b) . In MG132-treated control cells, the levels of ubiquitinated NFATc1 were slightly higher than those in untreated cells (Fig. 8b) . These results indicate that the presence of KBTBD11 enhances ubiquitination of NFATc1. To confirm whether the KBTBD11 and Cullin3 affects ubiquitination of NFATc1, we treated the control and KBTBD11-overexpressing cells with MLN4924, which works as an inhibitor of Cullin ligases by blocking neddylation of the enzyme (Fig. 8c ). After RANKL stimulation for 4 days, immunoprecipitation for ubiquitinated NFATc1 revealed that MLN4924 treatment markedly inhibited the levels of ubiquitinated NFATc1 in www.nature.com/scientificreports www.nature.com/scientificreports/ MG132-treated cells, suggesting the involvement of a Cullin ligase(s) in ubiquitination of NFATc1 (Fig. 8c ). Taken together, these results indicate that NFATc1 is possibly one of the substrates ubiquitinated under the influence of the KBTBD11 and Cullin3.
Discussion
In this study, we showed that KBTBD11 expression increased during osteoclast differentiation. The KBTBD11 knockdown enhanced osteoclastogenesis; namely, KBTBD11-depleted osteoclasts displayed larger formation than control osteoclasts and showed increased expression of osteoclast marker genes. In contrast, KBTBD11 overexpression abrogated osteoclast differentiation concomitant with decreased expression of osteoclast marker genes. Among the major signaling pathways involved in osteoclast differentiation, KBTBD11 predominantly affected NFATc1 signaling. Mechanistically, KBTBD11 interacted with the E3 ubiquitin ligase Cullin3. Moreover, KBTBD11 overexpression induced accumulation of ubiquitinated NFATc1, indicating that the KBTBD11 and Cullin3 participate in degradation of ubiquitinated NFATc1 by the proteasome. Given that NFATc1 is known to regulate osteoclast differentiation, the KBTBD11 and Cullin3 are probably involved in regulating the protein levels of NFATc1 by ubiquitination. Thus, KBTBD11 negatively regulates osteoclast differentiation by means of interaction with Cullin3 via NFATc1 degradation. Based on these findings, the KBTBD11 expression is induced during osteoclastogenesis, and KBTBD11 preferentially interacts with Cullin3. The KBTBD11 and Cullin3 possibly cause ubiquitination of NFATc1. The ubiquitinated NFATc1 is probably degraded by the proteasome. Thus, it is likely that KBTBD11 negatively controls the protein levels of NFATc1 qualitatively and quantitatively at a post-translational level.
One of our important findings is that the KBTBD11 and Cullin3 possibly cause NFATc1 ubiquitination. Among the six major signaling pathways participating in osteoclast differentiation, only NFATc1 expression was correlated with osteoclast differentiation. KBTBD11 knockdown increased NFATc1 expression, and conversely, KBTBD11 overexpression decreased NFATc1 expression. Meanwhile, the phosphorylation levels of JNK, IκB, ERK, Akt, and p-38 were indistinguishable between control and KBTBD11-overexpressing RAW-D cells. These results also indicate that KBTBD11 and Cullin3 possibly regulate the quantitative regulation of NFATc1 expression.
Among seven Cullin proteins in mammalian cells, only Cullin3 associates with BTB-Kelch proteins. Accumulating evidence from biochemical and structural analyses has indicated that BTB-Kelch proteins directly bind to Cullin3 at N-terminal BTB domain 20, 22, 23 . Therefore, we can speculate that the N-terminal BTB domain of Cullin3 is important for the interaction with KBTBD11. www.nature.com/scientificreports www.nature.com/scientificreports/ As a major function of BTB-Kelch proteins, some members are reported to participate in skeletal muscle development 21 . Mutations in human KLHL9 24 , KBTBD13 25 , KLHL40 (KBTBD5) [26] [27] [28] , and/or KLHL41 (KBTBD10) 29 , all of which interact with Cullin3, cause skeletal muscle disorders 21, 23, 30 . In the case of a lack of Kelch proteins, the absence of the ubiquitin ligase complex causes accumulation of abnormal proteins, resulting in skeletal muscle diseases 21 . Among these, the function of KLHL41 in myoblasts during muscle differentiation is reminiscent of that of KBTBD11 in RANKL-stimulated macrophages during osteoclast differentiation. Importantly, myoblasts undergo cell-cell fusion to form multinucleated cells, a process termed as myogenesis. KLHL41 expression is gradually increased in myoblasts during muscle differentiation 31 . Knockdown of KLHL41 causes enhanced differentiation at an early phase 32 . However, in the late phase of differentiation, the KLHL41 knockdown reduces the percentage of cells with more than five nuclei, thus pointing to successful inhibition of differentiation 32 . In an analogous fashion, the KBTBD11 knockdown enhanced osteoclastogenesis, while the KBTBD11 overexpression inhibited osteoclast differentiation in our study. Therefore, it is of interest to examine multinuclear mechanisms of BTB-Kelch proteins in osteoclastogenesis versus myogenesis.
Cell differentiation is strictly controlled by negative-feedback mechanisms to prevent over-stimulation. Since NFATc1 is an essential transcriptional factor for osteoclastogenesis 3, 33 , it is regulated by many epigenetic mechanisms, such as de-acetylation, methylation, miRNA and ubiquitination 34 . Among these, it is likely that ubiquitination of NFATc1 is controlled by several E3 ubiquitin ligases. RING finger-type E3 ubiquitin ligases Cbl-b and c-Cbl, negatively regulate osteoclast formation 15 . During late-stage osteoclastogenesis, after M-CSF-mediated c-Src kinase activation, activated Cbl-b and c-Cbl cause NFATc1 ubiquitination, resulting in proteasomal degradation 15 . JMJD5, a Jumonji C domain-containing protein, also negatively controls osteoclast differentiation by promoting degradation of ubiquitinated NFATc1 35 . JMJD5 acts as a hydroxylase, thereby promoting the interaction of hydroxylated NFATc1 and E3 ubiquitin ligase complex, including von Hippel-Lindau tumor suppressor 35 . However, it is unclear how several ubiquitin ligases regulate NFATc1. It is possible to speculate that multiple negative regulatory mechanisms mediated by several ubiquitin ligases are required for the maintenance of NFATc1 for bone homeostasis, since NFATc1 has auto-amplification mechanisms.
In conclusion, this study shows that KBTBD11 negatively regulates osteoclast differentiation by interaction with Cullin3 via NFATc1 degradation.
Methods
Reagents. Recombinant RANKL was prepared as described previously 36 . α-Minimum essential medium www.nature.com/scientificreports www.nature.com/scientificreports/ Mouse monoclonal anti-NFATc1 (nuclear factor of activated T-cells, cytoplasmic 1) (Cat. No. sc-7294) were from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Mouse monoclonal anti-Src (proto-oncogene tyrosine-protein kinase) (Cat. No. 05-184) was purchased from Upstate Biotechnology (Lake Placid, NY, USA). Anti-CTSK antibody was prepared as previously described 37 . All other reagents, including phenylmethylsulfonyl fluoride (PMSF) and the protease inhibitor cocktail, were obtained from Sigma-Aldrich. MLN4924 (Cat. No. CEM-CS-0348) was purchased from Chemscene LLC (Monmouth Junction, NJ, USA). The cells were incubated without or with 20 μM MG132 for 5 h, and were lysed in a lysis buffer. The lysates were subjected to western blot analysis using anti-NFATc1 and anti-GAPDH antibodies. (b) Control or KBTBD11-overexpressing RAW-D cells were cultured with RANKL (100 ng/mL) for 2 days. The cells were incubated without or with 20 μM MG132 for 5 h, and were lysed in a lysis buffer. The lysates were immunoprecipitated with anti-NFATc1 anti-body. After addition of protein G-Sepharose, the binding proteins were eluted and subjected to western blot analysis using anti-ubiquitin. (c) Control or KBTBD11-overexpressing RAW-D cells were cultured with RANKL (100 ng/mL) for 4 days. The cells were incubated without or with 20 μM MG132 and 10 nM MLN4924 for 5 h, and were lysed in a lysis buffer. The lysates were immunoprecipitated with anti-NFATc1 anti-body. After addition of protein G-Sepharose, the binding proteins were eluted and subjected to western blot analysis using anti-ubiquitin. The experiments were performed independently 3 times.
Immunoprecipitation. Cells were washed twice with phosphate-buffered saline (PBS). Then, the cells were lysed in a lysis buffer (PBS containing 0.1% Triton X100, 10 mM N-ethylmaleimide, and proteinase inhibitors). After centrifugation at 25,000 × g for 10 min at 4 °C, the supernatants were immunoprecipitated with anti-Cullin3 anti-body that was immobilized on resin using the Co-immunoprecipitation Kit (Pierce, Thermo Scientific). For immunoprecipitation experiments with ubiquitinated NFATc1, the cells were lysed in the lysis buffer containing 10 mM N-ethylmaleimide. The cell lysates were quenched by 0.1% cysteine, and incubated with anti-NFATc1 antibody for 1 hr followed by overnight incubation with protein G-Sepharose at 4 °C. After addition of protein G-Sepharose, the beads were washed four times with the lysis buffer, and then washed once with PBS. The sedimented beads were resuspended in Laemmli's sample buffer containing 100 mM DTT, were boiled and subjected to western blot analysis.
Western blot analysis. Western blot analysis was performed according to previously described methods 38 . Briefly, after washing, cells were lysed in a cell lysis buffer [50 mM Tris-HCl (pH 8.0), 1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate (SDS), 150 mM NaCl, 1 mM PMSF, and proteinase inhibitor cocktail]. The same protein amounts (5 µg) were subjected to SDS-polyacrylamide gel electrophoresis (PAGE), followed by transfer onto a polyvinylidene difluoride membrane. The blots were blocked with 5% milk in Tris-buffered saline for 1 h at 25 °C, incubated with various primary antibodies overnight at 4 °C, washed, incubated with horseradish peroxidase-conjugated secondary antibodies, and finally detected with ECL-Prime (GE Healthcare Life Sciences, Tokyo, Japan). The immunoreactive bands were analyzed using a LAS-4000mini (Fujifilm, Tokyo, Japan).
Quantitative PCR analysis. Total RNA was extracted using the TRIzol Reagent (Invitrogen). Reverse transcription was performed using an oligo(dT)15 primer (Promega, Madison, WI, USA) and ReverTra Ace (Toyobo, Osaka, Japan). Quantitative RT-PCR was performed using an MX3005P QPCR system (Agilent Technologies, La Jolla, CA, USA). The cDNA was amplified using Brilliant III Ultra-Fast SYBR QPCR Master Mix (Agilent). The following primer sets were used (5′ to 3′): KBTBD11, forward: GTT TCG TGC CTT CTC AGG AC, and reverse: GCT TCT CAG GCA GGT TGA GT; NFATc1, forward: TCATCCTGTCCAACACCAAA and reverse: TCACCCTGGTGTTCTTCCTC;
OC-STAMP, forward: TGGGCCTCCATATGACCTCGAGTAG and reverse: TCAAAGGCTTGTAAATTGGA GGAGT; DC-STAMP, forward: CTAGCTGGCTGGACTTCATCC and reverse: TCATGCTGTCTAGGAGA CCTC; SRC (Src), forward: AGAGTGCTGAGCGACCTGTGT and reverse: GCAGAGATGCTGCCTT-GGTT; CTSK, forward, CAGCTTCCCCAAGATGTGAT; reverse: AGCACCAACGAGAGGAGAAA; CALCR (calcitonin receptor), forward: CGCATCCGCTTGAATGTG and reverse: TCTGTCTTTCCCCAG-GAAATGA; MMP9, forward, TATTTTTGTGTGGCGTCTGAGAA and reverse: GAGGTGGTTTAGCCGGTGAA; GAPDH, forward: ACCACAGTCCATGCCATCAC; reverse: TCCACCACCCTGTTGCTGTA. TRAP staining. TRAP staining was performed by the method described previously 38 . Briefly, after fixation with 4% paraformaldehyde, cells were incubated with 0.01% naphthol AS-MX phosphate (Sigma-Aldrich) and 0.05% fast red violet LB salt (Sigma-Aldrich, Tokyo, Japan) in the presence of 50 mM sodium tartrate and 90 mM sodium acetate (pH 5.0) for TRAP activity. TRAP-positive red cells with three or more nuclei were considered as mature osteoclasts.
Bone resorption assay. Bone resorption assay was performed by the method described previously 38 . Briefly, RAW-D cells were seeded onto Osteo Assay Stripwell Plates coated with thin calcium phosphate films (Corning, New York, USA), and incubated with RANKL (500 ng/mL) for 1 day. After that, the cells were incubated with siRNA (control or KBTBD11-specific), and then cultured for 6 days until multinucleated osteoclasts were formed in the presence of 500 ng/mL RANKL. After incubation, osteoclasts from RAW-D cells were dissolved in 5% sodium hypochlorite. The ratios of the resorbed areas to the total areas were calculated using the Image J software (http://rsbweb.nih.gov/ij/) as described previously.
